Summary
One hundred twenty-five patients with chronic hepatitis C were treated with natural IFNα or recombinant IFNα-2a, daily doses of 3 MU or 9MU, respectively. IFNs were given 6 times a week for the first 2 weeks followed by thrice weekly administration for 12 weeks or more. ANA, TMA, AMA and anti-DNA antibody newly developed in 8, 1, 2 and 1 patient, respectively. Furthermore, we encountered some cases in which underlying autoimmune disorders were throught to be exacerbated by IFNs. It is important to pay sufficient attention to the development of autoimmune diseases in IFN therapy for chronic hepatitis C.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med 1986;315: 1575–1578.
Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized double-blind placebo-controlled trial. N Engl J Med 1989;321: 1506–1510.
Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med 1989;321: 1501–1506.
Shindo M, Di Bisceglie AM, Cheung L, et al. Decrease in hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991;115: 700–704.
Mayet WJ, Hess G, Gerken G, et al. Treatment of type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 1989;10: 24–28.
Lisker-Melman M, Di Bisceglis AM, Usala SJ, et al. Development of thyroid disease during therapy of chronic viral hepatitis with interpheron alfa. Gastroenterology 1992;102: 2155–2160.
Burman P, Totterman TH, Oberg K, et al. Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endcrinol Metab 1986;63: 1086–1090.
Abdi EA, Brien W and Venner PM. Auto-immune thrombocytopenia related to interferon therapy. Scand J Haematol 1986;36: 515–519.
Akard LP, Hoffman R, Elias L, et al. Alpha interferon and immune hemolytic anemia. Ann Int Med 1986;105: 306.
Schilling PJ, Kurzrock R, Kantarjian H, et al. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 1991;68: 1536–1537.
Quesada JR and Gutterman JU. Psoriasis and alpha-interferon. Lancet 1986:1466–1468.
Conlon KC, Urba WJ, Smith JW, et al. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 1990;65: 2237–2242.
Candler RV, Rouse ST and Moore RN. Regulation of interleukin 1 production by alpha and beta interferons: Evidence for both direct and indirect enhancement. J Interferon Res 1985;5: 179–000.
Herberman RB, Ortaldo JR and Bonnard GD. Augmentation of natural and antibody dependent cell mediated cytotoxicity. Nature 1979;277: 221–223.
Glisler RH, Lindahl P and Gresser I. Effects of interferon on anti-body synthesis in vitro. J Immunol 1974;113: 438–444.
Revel M and Chebath J. interferon activated genes. Trends Biol Sci 1986;11: 166–170.
Sztein BM, Steeg P, Jhonson HM, et al. Regulation of human peripheral blood monocytes DR antigen expression in vitro by lymphokines and recombinant interferons. J Clin Invest 1984;73: 556–565.
Vento S, Garofano T, Di Perri G, et al. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 1 1991: 1183–1184.
Lenzi M, Ballardini G, Fusconi M, et al. Type 2 autoimmune hepatitis and hepatitis C virus infection. Lancet 1990;335: 258–259.
Garson JA, Lenzi M, Ring C, et al. Hepatitis C viraemia in adults with type 2 autoimmune hepatitis. J Med Virol 1991;34: 223–226.
Lenzi M, Johnson PM, McFarlane IG, et al. Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity. Lancet 1991;338: 277–280.
Mishiro S, Hoshi Y, Takeda K, et al. Non-A, non-B hepatitis specific antibodies directed at host-derived epitope: implication of autoimmune process. Lancet 1990;336: 1400–1403.
Matushita E, Unoura M, Furusawa A, et al. STudies on the mechanisms of devrelopment of autoimmune hepatitis. Acta Hepat Jap 1988;29: 1357–1361. (in Japanese)
Morimoto H, Wakabayashi T, Suzuki K, et al. Autoimmune hepatitis manifested by clinico-pathological features of acute hepatitis: report of two cases. Acta Hepat Jap 1991;12: 1148–1155. (in Japanese)
Maeda Y, Shibuya T, Toshima M, et al. a case of autoimmune chronic active hepatitis with initial features of acute hepatitis. In: Tsuji T, Sasaki H, Kameda, H, eds. Autoimmune liver diseases: Aspects of concept, pathogenesis and treatment. Tokyo: Nihon Igakukan, 1992 124–128.
Silva MO, Reddy R, Jeffers LJ, et al. Interferon-induced chronic active hepatitis? Gastroenterology 1991;101: 840–842.
Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 1992;102: 1406–1408.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yoshikawa, M., Sakamoto, T., MitorO, A. et al. Autoimmunity during alpha-interferon therapy for chronic hepatitis C. Gastroenterol Jpn 28 (Suppl 5), 109–114 (1993). https://doi.org/10.1007/BF02989219
Issue Date:
DOI: https://doi.org/10.1007/BF02989219